[Comparison of therapeutic effects between transcatheter arterial chemoembolization and transcatheter arterial-portal venous double chemoembolization in treatment of moderate and advanced stages of primary liver carcinoma].
OBJECTIVE
Many clinic data showed that it is difficult to control primary liver carcinoma (PLC) by transcatheter arterial chemoembolization (TACE) alone due to existence of double blood supply of liver by hepatic artery and portal vein. This study was designed to evaluate the efficacy of transcatheter arterial chemoembolization combined with portal venous chemoembolization (PVCE) in the treatment of moderate and advanced stages of PLC.


METHODS
Fifty-eight cases of moderate and advanced stages of PLC were treated with a combination of TACE and PVCE (TACE/PVCE group) and 118 patients with moderate and advanced stages of PLC were treated with TACE alone (TACE group).


RESULTS
(1)The total response rates were 86.2% in TACE+PVCE group and 69.5% in TACE group. The remarkable response rates were 31.0 % in TACE/PVCE group and 13.6% in TACE group (P< 0.05). (2)The half-year survival rates were 93.1% in TACE/PVCE group and 72.0% in TACE group (P< 0.05). The 1-year survival rates were 43.1% in TACE/PVCE group and 51.7% in TACE group. The 4-year survival rates were 6.9% in TACE/PVCE group and 5.1% in TACE group (P >0.05). (3) Side effects included fever, bellyache, white blood cell drop, hypohepatia, jaundice,and ascites. The degree of liver damage was positively associated with the amount of iodized oil.


CONCLUSIONS
The combination of TACE and PVCE appears to promote the short-term efficacy but not the long-term efficacy, compared with TACE alone for patients with moderate and advanced PLC.
Wu
Yao-Pan
YP
Department of Diagnostic Imaging & Intervention, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China. wyaopan@mail.china.com
Zhang
Wei-Zhang
WZ
Li
Li
L
Guo
Rong-Ping
RP
Xie
Chuan-Miao
CM
Cai
Pei-Qiang
PQ
D016461:Chemoembolization, Therapeutic / Q000379:methods*; D006499:Hepatic Artery; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D011169:Portal Vein; D015996:Survival Rate